Holli Bradish-Lane unveils The GLP-1 Exit Plan, a pioneering book designed to guide individuals safely off weight-loss ...

To address this, researchers tested a new strategy: combining semaglutide (the active ingredient in Ozempic and Wegovy) with an experimental drug called bimagrumab. Bimagrumab is a lab-made antibody ...

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO -4.99%) were lower by 4% as of 11 a.m. ET today. The move comes ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Viking Therapeutics stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 studies could pay off.

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.